Astrazeneca's Fasenra Gets Orphan Drug Designation for Autoimmune Disease

Astrazeneca's Fasenra Gets Orphan Drug Designation for Autoimmune Disease

Source: 
Yahoo/Zacks.com
snippet: 

AstraZeneca, plc’s AZN new asthma drug, Fasenra (benralizumab), was granted orphan drug designation by the FDA for the treatment of eosinophilic granulomatosis with polyangiitis (“EGPA”). The company is developing the drug for treating EGPA in a phase II study.